✦ LIBER ✦

Three New Drugs for Acute Lymphoblastic Leukemia: Nelarabine, Clofarabine, and Forodesine

✍ Scribed by Richard A. Larson

Book ID: 114474113
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 172 KB
Volume: 34
Category: Article
ISSN: 0093-7754
DOI: 10.1053/j.seminoncol.2007.11.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clofarabine-based chemotherapy for relap

Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience

✍ Pere Barba; Antonia Sampol; María Calbacho; José Gonzalez; Josefina Serrano; Pil 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 774 KB

Drug-drug interaction between methotrexa

Drug-drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia

✍ Parentelli, Anne-Sophie; Phulpin-Weibel, Aurélie; Mansuy, Ludovic; Contet, Audre 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Secondary acute lymphoblastic leukemia i

Secondary acute lymphoblastic leukemia in a child three years after treatment for medulloblastoma

✍ Casteels, Kristina ;Renard, Marleen ;Van Gool, Stefaan ;Uyttebroeck, Anne 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB

Laboratory Practice Guidelines for Detec

Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

✍ Jones, Dan; Kamel-Reid, Suzanne; Bahler, David; Dong, Henry; Elenitoba-Johnson, 📂 Article 📅 2009 🏛 American Society for Investigative Pathology 🌐 English ⚖ 243 KB

Association of delivered drug dose and o

Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features

✍ Gaynon, Paul S. ;Steinherz, Peter G. ;Bleyer, W. Archie ;Finklestein, Jerry Z. ; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB

Dose and dose intensity are believed critical for attaining a maximal therapeutic effect in drug-responsive tumor systems. Childhood acute lymphoblastic leukemia may be an example of such a drug-responsive system as it is cured with current chemotherapy in a majority of cases. Between August 1981 an

Ponatinib: A New Tyrosine Kinase Inhibit

Ponatinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

✍ Shamroe, C. L.; Comeau, J. M. 📂 Article 📅 2013 🏛 Harvey Whitney Books Company 🌐 English ⚖ 288 KB